Request Demo
Last update 23 Oct 2026
Conatumumab
Last update 23 Oct 2026
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms Conatumumab (USAN/INN), AMG-655 |
Target |
Action agonists |
Mechanism DR5 agonists(Tumor necrosis factor receptor superfamily member 10B agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 9532985H
Source: *****
Sequence Code 9532993L
Source: *****
Related
12
Clinical Trials associated with ConatumumabNCT01940172
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
NCT01327612
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
NCT00813605
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
100 Clinical Results associated with Conatumumab
Login to view more data
100 Translational Medicine associated with Conatumumab
Login to view more data
100 Patents (Medical) associated with Conatumumab
Login to view more data
32
Literatures (Medical) associated with Conatumumab30 Sep 2025PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma
Article
Author: Sun, Zhen ; Beijersbergen, Roderick L. ; Wang, Siying ; Gao, Qiang ; Jin, Haojie ; Lieftink, Cor ; Wang, Liqin ; Qin, Wenxin ; Zheng, Jiaojiao ; Lian, Shuo ; Ji, Shuyi ; Guan, Ming ; Zhu, Huijue ; Wu, Wei ; Wang, Jian ; Jia, Qi ; Shi, Yaoping ; Fan, Zhoulong ; Yang, Wu ; Li, Zhe ; Jansen, Robin A. ; Bernards, René ; Deng, Xuan ; Niu, Kongyan
Cholangiocarcinoma (CCA) remains a lethal malignancy with limited therapeutic options. Through genome-wide CRISPR-Cas9 screening, we identified the adenosine triphosphatase (ATPase) valosin-containing protein (VCP) as a critical dependency in CCA. Compound screens revealed that the VCP inhibitor CB-5339 potently suppresses CCA proliferation in a panel of patient-derived organoids by inducing cellular senescence. It is known that senescent cells persist, and this can contribute to therapy resistance. To address this, we combined CB-5339 with senolytic agents (ABT-263 and conatumumab), which selectively eliminate senescent CCA cells, resulting in enhanced tumor suppression both in vitro and in vivo. Clinical analysis showed that VCP overexpression in CCA patients correlates with poor prognosis. Our study unveils a “one-two punch” strategy, targeting VCP-mediated senescence followed by senolytic clearance, offering a promising therapeutic approach for CCA.
31 Dec 2022Drug deliveryQ2 · MEDICINE
Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers
Q2 · MEDICINE
ArticleOA
Author: Liu, Youqiang ; Zhao, Liyan ; Meng, Qingju ; Liu, Yibing ; Cui, Haijing ; Zhang, Futong ; Zhang, Hongxin
PURPOSE:
Colorectal cancer (CRC) is the third most frequently diagnosed cancer and this study aimed to develop a conatumumab decorated, irinotecan prodrug and quercetin co-loaded delivery system for combined and targeted colorectal cancer treatment.
METHODS:
A conatumumab (C) decorated, irinotecan prodrug (I-p) and quercetin (Q) co-encapsulated NLC (C I-p/Q NLC) was developed. In vitro and in vivo antitumor efficiency of NLC was evaluated on CRC cells and mice xenograft.
RESULTS:
The results showed that the HT-29 cells uptake of C I-p/Q NLC was over 70%. Reactive oxygen species (ROS) sensitive irinotecan prodrug formulation showed improved drug release ability in hypoxic conditions. C I-p/Q NLC showed significantly higher cytotoxicity than non-decorated NLC, single drug-loaded NLC and free drugs. In vivo studies in a CRC-bearing model corroborated the capability of nanoparticles for the inhibition of cancer, leading to a reduction of tumor growth without systemic toxicity.
CONCLUSION:
The conatumumab decorated, ROS sensitive prodrug contained combination nano-system is a promising platform for CRC therapy.
01 Oct 2020Advances in therapyQ3 · MEDICINE
Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review
Q3 · MEDICINE
Review
Author: Cai, Yue ; Xie, Xiaoyu ; Li, Weiwei ; Wu, Zehua ; Hu, Huabin ; Deng, Yanhong ; Zhang, Jianwei ; Ling, Jiayu
INTRODUCTION:
Although various therapies are available for the treatment of metastatic colorectal cancer (mCRC), there is lack of head-to-head evidence. Recent studies have demonstrated the efficacy of chemotherapy in combination with different biological agents including regorafenib in second-line therapy in patients with mCRC. We conducted a network meta-analysis (NMA) to estimate the relative efficacy and safety of regorafenib in combination with chemotherapy compared to other biological agents with chemotherapy combinations.
METHODS:
A literature search was conducted in PubMed, Embase, and Cochrane databases to identify all randomized controlled trials (RCTs) evaluating the efficacy and safety of bevacizumab, regorafenib, panitumumab, cetuximab, ramucirumab, conatumumab, ganitumab, and aflibercept in combination with chemotherapy against chemotherapy alone as second-line setting from inception to 7 February 2019 in patients with mCRC. The survival outcomes were analyzed by the frequentist statistical approach (R software, netmeta package) while the level of individual treatment arms was assessed using the Bayesian method (R software, gemtc package).
RESULTS:
We identified 12 articles involving eight RCTs studies analyzing 6805 patients. The studies compared bevacizumab (3), regorafenib (1), panitumumab (2), cetuximab (3), ramucirumab (1), conatumumab (1), ganitumab (1), and aflibercept (1) against chemotherapy alone as comparator. The progression-free survival (PFS) revealed that regorafenib performed better than aflibercept (HR 0.9631, 95% CI 0.6785-1.367), ganitumab (HR 0.7228, 95% CI 0.3985-1.3109), panitumumab (HR 0.9653, 95% CI 0.6781-1.3742), and ramucirumab (HR 0.9206, 95% CI 0.6504-1.303). Regorafenib performed better than bevacizumab (OR 0.797, 95% CI 0.328-1.88) in terms of tumor response. Safety analysis showed that regorafenib performed better in reducing grade ≥ 3 adverse events (AE) than cetuximab and conatumumab, neutropenia than conatumumab, and fatigue than cetuximab.
CONCLUSIONS:
Regorafenib combined with chemotherapy might be a potential alternative to conventional therapeutic options in second-line treatment of patients with metastatic colorectal cancer and could be considered as the best option for treating patients with KRAS and BRAF mutated mCRC. However future RCTs are needed to confirm these results.
100 Deals associated with Conatumumab
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D09329 | Conatumumab | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Carcinoid Tumor | Phase 2 | United States | 03 Mar 2011 | |
| Carcinoid Tumor | Phase 2 | Poland | 03 Mar 2011 | |
| Carcinoid Tumor | Phase 2 | Spain | 03 Mar 2011 | |
| Lymphoma | Phase 2 | United States | 03 Mar 2011 | |
| Lymphoma | Phase 2 | Poland | 03 Mar 2011 | |
| Lymphoma | Phase 2 | Spain | 03 Mar 2011 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | - | 16 Jan 2009 | |
| Colorectal Cancer | Phase 2 | - | 16 Jan 2009 | |
| Neoplasm Metastasis | Phase 2 | - | 16 Jan 2009 | |
| Ovarian Cancer | Phase 2 | - | 16 Jan 2009 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 138 | (Phase 1b AMG 655 3mg/kg) | agfoiidofm = eajhiqmmjs wieceqjzka (jsjszlyrhh, ghognlcrop - uvhbjboosj) View more | - | 17 Oct 2024 | ||
(Phase 1b AMG 655 10mg/kg) | agfoiidofm = vsphzfoufd wieceqjzka (jsjszlyrhh, ujmokdeabt - bttttotbbh) View more | ||||||
Phase 1/2 | 89 | bvmczbmych = uogrvkqibb yrtlurzwgd (kykmkeqgrz, vszmvnlnwt - sgsrflponb) View more | - | 20 Aug 2024 | |||
bvmczbmych = dhtqbybbxs yrtlurzwgd (kykmkeqgrz, gmnivmmika - twebdiboyv) View more | |||||||
Phase 2 | 12 | (20050118: Ganitumab 20 mg/kg) | vxeqyrxdjm = rpkltryebs enapitsoeb (vgvgddteva, pippqdmjab - vnscqfsrvj) View more | - | 21 Feb 2021 | ||
(20050171: Conatumumab 0.45 mg/kg) | vxeqyrxdjm = yrogozcrdk enapitsoeb (vgvgddteva, oivpsgzewi - tzqnqflssy) View more | ||||||
Not Applicable | 78 | muxzmuvvzw(pydpryqlab) = aokubahfil udnsdjrrqw (anzserwlvx ) | - | 01 Mar 2015 | |||
Phase 1/2 | 53 | zqjghaevhj = zvfpzhgtvf xlglvfbakm (hdvdkuvltw, ovzzkwgsvc - sciwxqzckt) View more | - | 06 Feb 2014 | |||
Phase 2 | Advanced Lung Non-Small Cell Carcinoma First line | 172 | Paclitaxel-carboplatin + Conatumumab 3 mg/kg | rvwxjdhzkh(kghukyfgdr) = mdsibfdvon xmzdvjohsm (knntinryie, 4.1 - 6.3) | Negative | 01 Mar 2013 | |
Paclitaxel-carboplatin + Conatumumab 15 mg/kg | rvwxjdhzkh(kghukyfgdr) = wpayijnyvm xmzdvjohsm (knntinryie, 3.2 - 6.5) | ||||||
Phase 1 | 9 | kgcajcfcbg(vdsxipvmys) = occurred in 2 pts tpdjxpfvjg (kgzoxdrhza ) View more | - | 20 May 2010 | |||
Phase 1 | 12 | AMG 655 + PC | yaywvdhang(mealywmxui) = flavlixvir noaavgnhcp (gjrmhapafl, 1.5 - 7.0) | - | 20 May 2009 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free